150 related articles for article (PubMed ID: 33313608)
21. [4th Hungarian Breast Cancer Consensus Conference - Radiotherapy guidelines].
Polgár C; Kahán Z; Csejtei A; Gábor G; Landherr L; Mangel L; Mayer Á; Fodor J
Magy Onkol; 2020 Dec; 64(4):371-383. PubMed ID: 33313611
[TBL] [Abstract][Full Text] [Related]
22. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
23. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Kaufmann M; von Minckwitz G; Mamounas EP; Cameron D; Carey LA; Cristofanilli M; Denkert C; Eiermann W; Gnant M; Harris JR; Karn T; Liedtke C; Mauri D; Rouzier R; Ruckhaeberle E; Semiglazov V; Symmans WF; Tutt A; Pusztai L
Ann Surg Oncol; 2012 May; 19(5):1508-16. PubMed ID: 22193884
[TBL] [Abstract][Full Text] [Related]
24. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.
Farshid G; Bilous M; Morey A; Fox S; Lakhani S; Loi S; Bell R; Spillane A
Pathology; 2019 Jun; 51(4):345-348. PubMed ID: 31076089
[TBL] [Abstract][Full Text] [Related]
25. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
26. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel.
Kaufmann M; Pusztai L;
Cancer; 2011 Apr; 117(8):1575-82. PubMed ID: 21472705
[TBL] [Abstract][Full Text] [Related]
27. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
28. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
29. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).
Paluch-Shimon S; Pagani O; Partridge AH; Abulkhair O; Cardoso MJ; Dent RA; Gelmon K; Gentilini O; Harbeck N; Margulies A; Meirow D; Pruneri G; Senkus E; Spanic T; Sutliff M; Travado L; Peccatori F; Cardoso F
Breast; 2017 Oct; 35():203-217. PubMed ID: 28822332
[TBL] [Abstract][Full Text] [Related]
30. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.
Honecker F; Aparicio J; Berney D; Beyer J; Bokemeyer C; Cathomas R; Clarke N; Cohn-Cedermark G; Daugaard G; Dieckmann KP; Fizazi K; Fosså S; Germa-Lluch JR; Giannatempo P; Gietema JA; Gillessen S; Haugnes HS; Heidenreich A; Hemminki K; Huddart R; Jewett MAS; Joly F; Lauritsen J; Lorch A; Necchi A; Nicolai N; Oing C; Oldenburg J; Ondruš D; Papachristofilou A; Powles T; Sohaib A; Ståhl O; Tandstad T; Toner G; Horwich A
Ann Oncol; 2018 Aug; 29(8):1658-1686. PubMed ID: 30113631
[TBL] [Abstract][Full Text] [Related]
31. [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
Penault-Llorca F; Vincent-Salomon A; MacGrogan G; Roger P; Treilleux I; Valent A; Mathieu MC; Antoine M; Becette V; Bor C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Devouassoux M; Fiche M; Fondrevelle ME; Fridman V; Garbar C; Genin P; Ghnassia JP; Haudebourg J; Laberge-Le Couteulx S; Loussouarn D; Maran-Gonzalez A; Marcy M; Michenet P; Poulet B; Sagan C; Trassard M; Verriele V; Arnould L; Lacroix-Triki M;
Ann Pathol; 2014 Oct; 34(5):352-65. PubMed ID: 25439988
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
Ellis PM; Blais N; Soulieres D; Ionescu DN; Kashyap M; Liu G; Melosky B; Reiman T; Romeo P; Shepherd FA; Tsao MS; Leighl NB
J Thorac Oncol; 2011 Aug; 6(8):1379-91. PubMed ID: 21709590
[TBL] [Abstract][Full Text] [Related]
33. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Press MF; Sauter G; Buyse M; Fourmanoir H; Quinaux E; Tsao-Wei DD; Eiermann W; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Mackey JR; Bee V; Ma Y; Villalobos I; Campeau A; Mirlacher M; Lindsay MA; Slamon DJ
J Clin Oncol; 2016 Oct; 34(29):3518-3528. PubMed ID: 27573653
[TBL] [Abstract][Full Text] [Related]
34. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
[TBL] [Abstract][Full Text] [Related]
35. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma.
Lazovich D; Solomon CC; Thomas DB; Moe RE; White E
Cancer; 1999 Aug; 86(4):628-37. PubMed ID: 10440690
[TBL] [Abstract][Full Text] [Related]
36. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
37. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
Burgués O; López-García MÁ; Pérez-Míes B; Santiago P; Vieites B; García JF; Peg V
Clin Transl Oncol; 2018 Mar; 20(3):382-391. PubMed ID: 28795336
[TBL] [Abstract][Full Text] [Related]
38. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
39. Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
Li X; Zhang Y; Meisel J; Jiang R; Behera M; Peng L
Breast Cancer Res Treat; 2018 Sep; 171(2):303-313. PubMed ID: 29948405
[TBL] [Abstract][Full Text] [Related]
40. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Giuliano AE; Connolly JL; Edge SB; Mittendorf EA; Rugo HS; Solin LJ; Weaver DL; Winchester DJ; Hortobagyi GN
CA Cancer J Clin; 2017 Jul; 67(4):290-303. PubMed ID: 28294295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
